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Mutant Kras- and p16-regulated NOX4 activation
overcomes metabolic checkpoints in development
of pancreatic ductal adenocarcinoma
Huai-Qiang Ju1,2, Haoqiang Ying2, Tian Tian1, Jianhua Ling2, Jie Fu2, Yu Lu2, Min Wu2, Lifeng Yang3, Abhinav
Achreja3, Gang Chen4, Zhuonan Zhuang2, Huamin Wang5, Deepak Nagrath3, Jun Yao2, Mien-Chie Hung2,6,
Ronald A. DePinho6,7, Peng Huang1,4,6, Rui-Hua Xu1 & Paul J. Chiao2,6
Kras activation and p16 inactivation are required to develop pancreatic ductal adenocarci-
noma (PDAC). However, the biochemical mechanisms underlying these double alterations
remain unclear. Here we discover that NAD(P)H oxidase 4 (NOX4), an enzyme known to
catalyse the oxidation of NAD(P)H, is upregulated when p16 is inactivated by looking at gene
expression proﬁling studies. Activation of NOX4 requires catalytic subunit p22phox, which is
upregulated following Kras activation. Both alterations are also detectable in PDAC cell lines
and patient specimens. Furthermore, we show that elevated NOX4 activity accelerates
oxidation of NADH and supports increased glycolysis by generating NADþ , a substrate for
GAPDH-mediated glycolytic reaction, promoting PDAC cell growth. Mechanistically, NOX4
was induced through p16-Rb-regulated E2F and p22phox was induced by KrasG12V-activated
NF-kB. In conclusion, we provide a biochemical explanation for the cooperation between p16
inactivation and Kras activation in PDAC development and suggest that NOX4 is a potential
therapeutic target for PDAC.
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T
he mutational activation of Kras is an early genetic
alteration in the development of pancreatic ductal
adenocarcinoma (PDAC). This alteration has been
detected in nearly 95% of PDAC cases, and mutational
inactivation of the p16INK4a (hereafter referred to as p16) tumour
suppressor gene can be identiﬁed inB80–90% of PDAC cases1–3.
Previous studies showed that KrasG12D played critical roles in
initiating and maintaining PDAC, however, activation of Kras
alone may not be sufﬁcient to initiate tumorigenesis4,5. The
mutant Kras mouse models have demonstrated that additional
inactivation of p16/p14 or p53 dramatically accelerated the
progression of KrasG12D initiated PDAC6,7. Recent studies by
our group and others showed that KrasG12V activation led to
suppression of mitochondrial respiratory activity and rendered
the cell more dependent on glycolysis6,8,9. Conversely, others
reported that mitochondrial reactive oxygen species (ROS)
generation is essential for KrasG12V-induced cell proliferation
and KrasG12V-mediated tumorigenicity10. Dysfunctional
mitochondria and increased aerobic glycolysis are two
important biochemical characteristics observed frequently in
cancer cells8,11,12. A metabolic switch from oxidative
phosphorylation in the mitochondria to glycolysis in the cytosol
in cancer cells has been well known as ‘Warburg effect’ for
decades13,14. Although reprogramming of cellular metabolism is
now recognized as a key event during tumorigenesis, the
molecular mechanisms that initiate this metabolic shift in
tumorigenesis remain elusive. Also, the Ras downstream
effectors in tumorigenesis are elusive, the mechanisms by which
inactivated p16 cooperates with oncogenic Kras to bypass the
metabolic checkpoint through activation of speciﬁc signalling
pathways essential for KrasG12V-mediated tumorigenesis remain
unclear.
The family of NAD(P)H oxidases (NOX) consists of ﬁve
members (NOX1-5) and the small membrane-bound cata-
lytic subunit (p22phox) required for their activation. As ROS-
generating enzymes, all the NOX members have the capacity
to oxidize the substrates NADPH or NADH to NADPþ or
NADþ , which in turn results in formation of superoxide15,16.
Previous studies showed that NOX oxidases can effect several of
the hallmarks of cancer, including genomic instability,
autonomous growth and survival, invasion and metastasis,
possibly because of the alteration of redox-linked signalling
systems that are inﬂuenced by NOX-derived ROS17. However,
the biochemical roles for speciﬁc NOX complexes in cancer that
are relevant to cellular metabolism and the ‘Warburg effect’
remain unexplored.
We previously demonstrated that the expression of mutant
Kras and the silencing of KrasG12V-induced p16 expression in
hTERT-immortalized human pancreatic nestin-positive epithelial
(HPNE) cells resulted in transformation in vitro and in
development of PDAC in vivo5, Overexpression of NOX4 was
identiﬁed in HPNE/KrasG12V/shp16 cells, veriﬁed in PDAC cells
and patient specimens. NOX4 has been reported to play an
important pro-survival role in pancreatic cancer via unclear
mechanisms18,19. However, the function and molecular mecha-
nisms of NOX4 activation in reprogramming the metabolism,
tumorigenic transformation and pancreatic carcinogenesis
remained unknown.
In the present study, we investigate the function of NOX4 in
KrasG12V activation- and p16 inactivation-induced PDAC and
explored the underlying regulatory mechanisms. We show that
NOX4 activity is activated by increased expression of both NOX4
by p16-Rb-E2F and p22phox via KrasG12V-NF-kB pathways to
overcome metabolic checkpoints to enable initiation of PDAC
development. Our ﬁndings suggest that NOX4 is a potential
therapeutic target for cancer therapy.
Results
Mutant Kras and p16 increase NOX4 activity. To study the
mechanisms of tumorigenesis in the pancreas, we established an
HPNE cell model expressing KrasG12V or KrasG12V/p16shRNA5.
We found that activation of KrasG12V alone, which was not
sufﬁcient to initiate tumorigenesis in HPNE cells, induced high
expression of p16 (Fig. 1a). It is well known and we conﬁrmed
that loss of p16 is the most common mutation in PDAC cells,
PanIN (pancreatic intraepithelial neoplasia) and PDAC tissues
(Supplementary Fig. 1a,b). Interestingly, silencing p16 expression
in KrasG12V cells resulted in tumorigenic transformation and
development of PDAC in an orthotopic xenograft mouse model5.
The analysis of Kras copy number indicates the ratio between the
HPNE/KrasG12V and HPNE cells is about 4 times (Fig. 1a), which
is consistent with the recent ﬁnding that mutant Kras copy gains
are positively selected during tumour progression in KPC lung
cancer mouse model20,21. To elucidate the downstream pathways
activated by oncogenic Kras and inactivated p16 in human
pancreatic tumorigenesis, we proﬁled gene expression in
HPNE/KrasG12V/shp16 and HPNE/KrasG12V cells using cDNA
microarray analysis (Fig. 1b). Bioinformatics analysis identiﬁed
614 genes whose expression was signiﬁcantly increased on p16
knockdown. Figure 1c shows the functional categories of the
upregulated genes as predicted by gene set enrichment and
pathway analyses. It indicated that the most elevated genes in
tumorigenic HPNE/KrasG12V/shp16 cells were associated with
metabolic processes. NOX4, a key enzyme known to catalyse the
oxidation of NADPH or NADH to NADPþ or NADþ , was the
only metabolic enzyme among the top ten highly expressed genes
in response to p16 knockdown in our microarray (Fig. 1b;
Supplementary Table 1). Oncogenic Kras was shown to alter
metabolism, but how mutant Kras induces metabolic repro-
gramming that contributes to tumorigenic transformation is
unknown. To illuminate the mechanistic links between activated
Kras, inactivated p16 and overexpressed NOX4 in regulation of
metabolism, we investigated whether and how energy metabolism
was regulated by NOX4, and how oncogenic Kras cooperates with
inactivated p16 to increases the expression and activity of NOX4.
To verify the expression of NOX4 and its catalytic subunit
p22phox in HPNE, HPNE/KrasG12V and HPNE/KrasG12V/shp16
cells, we performed qPCR and immunoblotting analysis. As
shown in Fig. 1d, p22phox expression was induced by KrasG12V
in both HPNE/KrasG12V and HPNE/KrasG12V/shp16 cells, while
NOX4 was induced only in HPNE/KrasG12V/shp16 cells at both
the mRNA and protein levels. Further analysis also revealed
similar results after depletion of p16 using two different siRNAs
in HPNE/KrasG12V cells (Fig. 1h). Moreover, the activation
of Kras in HPNE cells resulted in a moderate increase of NOX
activity, and silencing of p16 in HPNE/KrasG12V cells led
a further increase in NOX activity (Fig. 1e). Consistent with
NOX as a major source of ROS17, HPNE/KrasG12V and HPNE/
KrasG12V/shp16 cells showed a substantial increase in superoxide
(O2 ) levels. In response to NOX-induced ROS stress, the
cellular glutathione (GSH) and GSH/GSSG ratio was signiﬁcantly
increased in HPNE/KrasG12V and HPNE/KrasG12V/shp16 cells
(Supplementary Fig. 1c,d). Taken together, these data suggested
that activation of Kras with silencing of p16 led to NOX-induced
ROS generation and a compensatory increase in cellular
antioxidant activity. To further verify these above ﬁndings, we
examined the expression and activities of NOX4 and p22phox in
human pancreatic ductal epithelial (HPDE)/KrasG12V and
HPDE/KrasG12V/shp16 cells derived from the nontumorigenic
immortalized HPDE cells22. Consistent with our observations in
the HPNE cell models, NOX4 expression, NOX activity and basal
O2 levels were signiﬁcantly elevated in HPDE/KrasG12V and
HPDE/KrasG12V/shp16 cells than in parental HPDE cells
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Figure 1 | Activated Kras or silenced p16 increased NOX4/p22phox expression and elevated NOX activity. (a) The expression of Kras and p16 was
analysed by immunoblotting in HPNE control, HPNE/Kras and HPNE/KrasG12V/shp16 cells. The copy numbers of KrasWT and KrasG12V were analysed by
qPCR assay in these cells. (b) Heat map of gene expression between HPNE/Kras and HPNE/KrasG12V/shp16 cells identiﬁed using cDNA microoarray.
(c) Functional categorization of 614 genes upregulated in response to p16 suppression in HPNE/KrasG12V cells. (d,f) The expression of NOX4 and p22phox
was analysed by qPCR and immunoblotting in indicated cells. (h) The expression of NOX4, p22phox and p16 was analysed by immunoblotting in HPNE/
KrasG12V, Colo357 and Capan-2 cells transfected with two independent p16 siRNAs. (e,g,i) NOX activity was determined in indicated cells by measuring
NADPH-dependent superoxide (O2
 ) generation with the lucigenin-enhanced chemiluminescence assay. b-actin was used as the internal loading control.
Each bar represents the mean±s.d. Data in d,e,g,i are presented as mean±s.d. (n¼ 3). **Po0.01 for indicated comparison (one-way analysis of variance
(ANOVA) with the Newman Keul’s multiple comparison test).
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(Fig. 1f,g; Supplementary Fig. 1e). Further analysis revealed that
the expression of NOX4 level was also increased after siRNA
depletion of p16 in Colo357 and Capan-2 cells with wild-type
p16, however the expression of p22phox level was not changed on
p16 depletion (Fig. 1h). NOX activity and cellular O2 levels were
also signiﬁcantly increased after siRNA depletion of p16 in these
cells (Fig. 1g,i; Supplementary Fig. 1f). Altogether, these data
suggest that either activation of Kras or inactivation of p16
induces NOX activation by increasing the expression of NOX4 or
p22phox in HPNE, HPDE and PDAC cells.
NOX4 and p22phox are overexpressed in PDAC. To determine
the role of NOX in pancreatic tumorigenesis, we examined the
pancreas-speciﬁc expression of the ﬁve NOX family members and
the catalytic subunit p22phox in HPNE cells and 11 indicated
PDAC cell lines. RT-PCR analysis showed that both NOX4 and
p22phox mRNAs were expressed in HPNE and all the tested
PDAC cells (Supplementary Fig. 2a,b). NOX2 and NOX5
could be detected in only few cells, whereas NOX1 and NOX3
expression were not detectable in these cell lines (Supplementary
Fig. 2b). The mRNA levels of NOX4 and p22phox were signi-
ﬁcantly increased in these PDAC cells or PDAC tissues
(Fig. 2a,b). Furthermore, immunoblotting analysis showed that
the NOX4 and p22phox protein levels were substantially higher
in PDAC cells than in nontumorigenic HPNE cells (Fig. 2c).
Consistently, the NOX activity were signiﬁcantly increased in
these PDAC cells (Fig. 2d). Thus, the expression levels of NOX4
and p22phox were overexpressed in PDAC cells and human
PDAC tissues.
To determine whether the expression of NOX4 was increased
in genetically engineered mouse models (GEMM) from Pdx1-Cre;
KrasG12D; p16F/F mice, immunohistochemical (IHC) analyses
were performed. NOX4 levels were substantially higher in these
tumours than in histologically normal pancreata from control
mice (Fig. 2e). Furthermore, IHC staining indicated that NOX4
levels were also elevated in PDAC tumours from iKras; p53L/þ
mouse model than in histologically normal pancreata from
control mice (Supplementary Fig. 2c). Thus, the expression levels
of NOX4 were increased in PDAC. Prior study showed that
p22phox levels were signiﬁcantly higher in pancreatic carcinoma
than in non-malignant tissues23. To further determine the clinical
relevance of NOX4 expression, we then analysed the expression
of NOX4 in a pancreatic tissue microarray representing 120 cases
of PDAC and 110 normal pancreatic acinous tissues. As shown in
Fig. 2f, 81.7% (98/120) of the pancreatic cancer tissues exhibited
high levels of NOX4, whereas only about 35.5% (39/110) of the
pancreatic tissues with normal histological appearance were
positive for NOX4 expression. Statistical analysis showed that
the increase in NOX4 expression in PDAC patients is highly
signiﬁcant (Po0.001) (Fig. 2f). Furthermore, the increased
expression of NOX4 and p22phox in PDAC analysed from
multiple cancer microarray data sets available from Oncomine
also supports our ﬁndings (Fig. 2g). Altogether, the data from
gene and protein proﬁling, cell lines and human and mice PDAC
tissues suggest that NOX4 expression is signiﬁcantly increased in
PDAC and NOX4 may play a key role in PDAC tumorigenesis.
NOX4 supports increased glycolysis by generating NADþ .
Cancer cells abnormally take up more glucose, processing
through aerobic glycolysis, then produces high levels of secreted
lactate, this phenomenon is called the ‘Warburg effect’, which
was interpreted as mitochondrial dysfunction14,24. Indeed, the
mitochondrial respiratory chain activity was reduced in
HPNE/KrasG12V and HPNE/KrasG12V/shp16 cells as evinced by
a substantial decrease in oxygen consumption rate (OCR)
(Fig. 3a). Accordingly, we found that glucose uptake and
lactate production levels were signiﬁcantly increased in HPNE/
KrasG12V/shp16 cells than in HPNE/KrasG12V and HPNE cells
(Fig. 3b). In the glycolytic pathway, glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) catalyses the conversion of glyce-
raldehyde-3-phosphate to D-glycerate 1,3-bisphosphate and
NADþ serving as a coenzyme is simultaneously reduced to
NADH25. NADþ is mainly regenerating from NADH by
lactate dehydrogenase isoform A (LDHA), which preferentially
converts accumulating pyruvate to lactate, to maintain glycolytic
ﬂux in cancer cells25. On the basis of the LDHA reaction,
the accumulation of lactate in tumour implies an increase
of NADH relative to NADþ : [Lactate]/[Pyruvate]p
[NADH][NADþ ], which means the NADþ is insufﬁcient in
cancer cells with higher glycolytic activity (Supplementary
Fig. 3a)26. Also, the negative feedback regulation of phospho-
fructokinase 1 (PFK1) by lactate act as strong inhibitors is
overridden by the allosteric activator, fructose-2,6-bisphosphate
(F2,6BP)27. Our further results also conﬁrmed that the cellular
NADþ /NADH and NADPþ /NADPH was signiﬁcantly decre-
ased in HPNE/KrasG12V/shp16 cells with higher lactate
concentration (Fig. 3b). Besides, the higher levels of NADPH
may produce by other metabolism pathways to counteract
oxidative stress and to support biomass production28. Because
NOX4 has the capacity to oxidize the substrates NADPH or
NADH to NADPþ or NADþ (ref. 15), we posited that NOX4
may function as a compensatory mechanism and accelerates
NADþ and NADPþ circulation to sustain cellular glycolysis and
pentose phosphate pathway activity in mitochondria-defective
pancreatic cancer cells.
To further substantiate the essentiality of NOX4 in NADþ and
NADPþ generation and glucose metabolism, we evaluated the
effect of NOX4 knockdown on cellular NADþ , NADPþ and
glycolytic activity. We measured cellular NADH and NADþ
contents in HPNE/KrasG12V/shp16 cells in the presence
and absence of NOX4 siRNA. Inhibition of NOX activity by
NOX4 siRNA knockdown caused signiﬁcant decreases in cellular
NADþ /NADH and NADPþ /NADPH ratios, by B30 and 20%,
respectively (Fig. 3c,d). Furthermore, knockdown of NOX4 also
signiﬁcantly decreased glucose uptake, lactate production and
ATP generation (Fig. 3d), indicating that NOX4 has an important
function in glycolytic metabolism of PDAC cells. Glycolytic
activity also was decreased in HPNE/KrasG12V/shp16, AsPc-1 and
Panc-28 cells with silenced p22phox or NOX4 (Fig. 3c,e,f). Also,
the decreased NADþ /NADH, NADPþ /NADPH ratios
and glycolytic activity were signiﬁcantly rescued in these cells
co-transfected with human NOX4 siRNA and siRNA resistance
NOX4 (NOX4-R) (Fig. 3f; Supplementary Fig. 3b,c).
To strengthen our experimental evidence, we established
NOX4-overexpressing HPNE/NOX4 cells and performed meta-
bolite isotope tracing experiments with 13 carbon labelled glucose
(U-13C6 Glu). We found that overexpression of NOX4 in
HPNE/NOX4 and HPNE/KrasG12V/shp16 in HPNE cells
increased pyruvate and lactate levels, thereby conﬁrming the
increased glucose to lactate conversion or glycolysis (Fig. 3g,h).
These ﬁndings unequivocally demonstrate that NOX4 plays an
essential role in maintaining high glycolytic activity in PDAC
cells by supplying NADþ from oxidation of NADH.
Expression of p22phox is upregulated by Kras-NF-jB pathway.
To interrogate the molecular mechanism through which p22phox
overexpression was induced by oncogenic Kras in PDAC cells, we
investigated whether inhibitors of the major Kras downstream
signalling pathways, including PI3K/Akt, ERK1/2 and NF-kB,
would decrease p22phox expression. We found that the expression
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of p22phox mRNA and protein levels were signiﬁcantly decreased
only in HPNE/KrasG12V/shp16, AsPc-1 and Panc-28 cells treated
with NF-kB inhibitor PDTC (Supplementary Fig. 4a,b). Further-
more, immunoblotting analysis showed that expression levels of
phosphorylated (p)-TAK1 and p-NF-kB (that is, activated
NF-kB/p65) were elevated in HPNE/Kras and HPNE/KrasG12V/
shp16 cells, indicating that the TAK1-NF-kB signalling pathway
was activated (Fig. 4a), which is consistent with our previous
published results29. Expression of p22phox and NOX activity were
decreased on induction of doxycycline (Dox)-regulated TAK1
shRNA in AsPc-1/iTAK1shRNA cells (Fig. 4b). Expression of
p22phox was induced by Dox following NF-kB activation in
iKras cells established from a PDAC mouse model with the Dox-
inducible KrasG12V transgene7 (Fig. 4c). Silencing of p65/NF-kB
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in HPNE/KrasG12V/shp16 cells with p65/NF-kB siRNA resulted
in downregulation of p22phox mRNA as determined by qPCR
analysis (Fig. 4d). In Panc-28 and AsPc-1 cells expressing a
mutant of IkBa with a defect in phosphorylation, p22phox
expression was substantially inhibited and NOX activity was
signiﬁcantly decreased (Fig. 4e,f). These results suggest that
p22phox overexpression was induced by NF-kB. To determine
whether p22phox expression is regulated at transcription by
NF-kB, we identiﬁed two NF-kB binding sites in 3-kb human
p22phox promoters (Fig. 4g). Chromatin immunoprecipitation
(ChIP) assays revealed that the NF-kB-BS-1 site had higher
binding activity in HPNE/KrasG12V/shp16, AsPc-1 and Panc-28
cells than in controls (Fig. 4h). The NF-kB-BS-1 site also showed
higher binding activity in all the HPNE/Kras and HPDE/Kras
cells compared with the parental cells (Fig. 4i). Further study
also indicates that the expression of p-NF-kB and p22phox was
obviously increased in AsPc-1 cells on TNFa stimulation (Fig. 4j).
In addition, we found that expression of NOX4 was induced by
Dox in mPDAC/iKras cells, which was consistent with the IHC
staining result using the transgenic iKras mice tissue. However,
NOX4 levels were unchanged in AsPc-1/iTAK1shRNA cells,
and Panc-28 or AsPc-1 cells expressing a mutant of IkBa
(Supplementary Fig. 4c–e). These ﬁndings demonstrate that
NF-kB is a major transcription factors binding to p22phox
promoter and mutant Kras-activated NF-kB mainly regulates
p22phox expression in PDAC cells.
NOX4 is upregulated via the p16-Rb-E2F pathway. The p16
pathway regulates cell cycle entry and progression, and loss of
p16 activates CDK4, which in turn phosphorylates retinoblastoma
protein (Rb), causing it to release the transcription factor
E2F (ref. 30). To further dissect whether loss of p16 upregulates
NOX4 expression via the Rb-E2F pathway in pancreatic cancer
cells, we performed an immunoblotting analysis, which showed
that Rb was strongly phosphorylated at sites S795 and S807/811
and that the expression level of nuclear E2F1 was increased in
HPNE/KrasG12V/shp16 cells (Fig. 5a). To determine the expres-
sion proﬁles of E2F family members in pancreatic cancer, RT-
PCR analyses were performed and revealed that E2F1, E2F3, E2F4
and E2F5 were all expressed in HPNE/KrasG12V/shp16, AsPc-1
and Panc-28 cells, while E2F2 was detected only in AsPc-1 cells
(Fig. 5b). E2F1 was expressed at the highest levels of all the E2F
family in these cells (Fig. 5b). RNAi depletion of E2F1, E2F3 E2F4
and E2F5 all resulted in downregulation of NOX4 expression in
HPNE/KrasG12V/shp16 and Panc-28 cells (Fig. 5c), demon-
strating that NOX4 expression is regulated by several E2F family
members. To demonstrate the regulation of NOX4 expression by
E2F1, we identiﬁed two E2F1 binding sites in 3-kb human NOX4
promoters (Fig. 5d). ChIP assays revealed that the E2F1-BS-1 site
showed higher binding activity in HPNE/KrasG12V/shp16, AsPc-1
and Panc-28 cells (Fig. 5e). We also found that NOX activity was
signiﬁcantly decreased after RNAi depletion of E2F1 in these cells
(Fig. 5f). However, further study revealed that the E2F binding
activity showed no obvious differences between the p16 wild-type
and mutant cells (Fig. 5g), consistence with the expression of
NOX4 in these cells (Fig. 2c). Considering that gene transcription
is a complicated process, it is likely that other transcription fac-
tors, co-activators or other cell cycle inhibitors beyond p16 are
involved in the regulation of NOX4. As known, p53-regulated p21
expression is decreased when p53 is knocked out. As the result,
CDK4 is activated and phosphorylates Rb, thus, leading to acti-
vation of E2F. Consistently, IHC staining indicated that the
expression of NOX4 was substantially higher in these PDAC from
iKras; p53L/þ mouse model as described above. Together,
although the E2F binding activity and the expression of NOX4 is
complicated, our results revealed that loss of p16 upregulates
NOX4 expression through the Rb-E2F signalling pathway in
PDAC cells.
NOX4 is a potential therapeutic target for PDAC. To further
substantiate whether inhibition of NOX4 expression would
reverse the tumorigenic phenotype induced by mutant Kras
and p16, we stably knocked down NOX4 expression in
HPNE/KrasG12V/shp16 cells using lentiviral NOX4 shRNAs
(Supplementary Fig. 5a). The depletion of NOX4 led to a
signiﬁcant decreases in NOX activity, cell growth and colony
formation of HPNE/KrasG12V/shp16 cells, and signiﬁcantly
decreased their tumorigenic potential in orthotopic xenograft
mice (Fig. 6a–c; Supplementary Fig. 5a). Next, we investigated the
effect of NOX4 on the kinetics of PDAC tumour progression by
subcutaneous injection. Similarly, we observed that the tumours
formed by NOX4-silenced cells grew at a much slower rate than
control tumours (Fig. 6d–f). As expected, we also observed that
knockdown of NOX4 signiﬁcantly decreased the glucose uptake
and lactate production levels, but increased the OCR in the
primary culture cells derived from subcutaneous xenograft mice
tumour tissue (Supplementary Fig. 5b). To test the role of NOX4
in PDAC cell survival, we established stably knocked down
NOX4 in AsPC-1 cells (Supplementary Fig. 5c). Suppression of
NOX4 expression also signiﬁcantly decreased NOX activity,
NADþ /NADH ratio, glucose uptake, lactate generation and led
to a signiﬁcant decrease in cell growth (Supplementary Fig. 5e,f).
Inhibition of NOX4 by the inhibitor DPI in AsPc-1 and Panc-28
cells also reduced cell viability with minimal toxicity to HPDE
and HPNE cells according to MTS assay (Supplementary
Fig. 6a,b), suggesting that DPI may selectively cause death of
PDAC cells. Importantly, we found that suppression of NOX4 by
shRNA or the inhibitor DPI signiﬁcantly suppressed PDAC
growth in vivo (Fig. 6g). IHC staining showed suppression of
NOX4 by shRNA or the inhibitor DPI also displayed lower cell
proliferation indices (Ki67-positive) and higher cell apoptosis
(TUNEL-positive) compared with control tumours (Fig. 6h).
We also established the inducible NOX4-konckdown cell line
(AsPc-1/i-shNOX4), and revealed that ‘Dox/on’ group mice
showed a signiﬁcant reduction in tumour burden compared with
the control group after 4 weeks of dox treatment (Fig. 6i;
Supplementary Fig. 5d). As such, we further assessed the impact
of DPI on transgenetic iKras; p53L/þ mice generated from
crossing iKras and conditional p53 knockout (p53L) alleles7. As
shown in Fig. 6j, following Dox treatment at 3 weeks of age,
all iKras; p53L/þ mice succumbed to PDAC between 14 and
18 weeks of age (median survival, 16 weeks), whereas the
DPI-treated group prolonged these mice survival with a median
survival of 20 weeks (Fig. 6j). We analysed the proliferative index
of the dissected tumours and found that the proliferation index
has rebounded in tumours from the DPI-treated group after
treatment for 16 weeks. That may explain why DPI treatment just
showed moderate effect (Supplementary Fig. 6c,d). These ﬁndings
demonstrate that NOX4 is essential for PDAC growth by
accelerating NADþ circulation thus maintaining the high levels
of glycolysis activity required for PDAC development driven by
Kras and loss of p16. Our results revealed that NOX4 is required
for PDAC development and pharmacologic targeting of NOX4
represents a potential novel therapeutic approach for pancreatic
cancer.
Discussion
That mutational activation of Kras and inactivation of p16 are
two signature genetic alterations required for development of
PDAC, and it has been demonstrated in mouse models that
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recapitulate the key events in pathogenesis of human
PDAC6,31,32. However, the biochemical mechanisms underlying
this function have remained unclear. As reported here, we
identiﬁed the mechanisms through which loss of p16 expression
cooperates with oncogenic Kras in metabolic reprogramming
from oxidative phosphorylation to glycolysis during PDAC
development. Although it has been shown that inactivation of
p16 and activation of Kras result in loss of a cell cycle checkpoint
and stimulation of cell proliferation33,34, our results have
unequivocally demonstrated that loss of p16 and oncogenic acti-
vation of Kras induce NOX4 activity for metabolic
reprogramming to maintain glycolysis and sustain cell
growth, thus providing a novel mechanistic explanation for the
requirement of inactivation of p16 and activation of Kras in
PDAC development.
Seventy years ago, Warburg observed that tumours produce
excess lactate in normoxic conditions and he interpreted this
phenomenon as mitochondrial dysfunction13,35. As proposed by
Vander Heiden et al. that cancer cells with a mitochondrial
respiration defect, such as those caused by oncogenic Kras,
require a high rate of glycolysis to produce sufﬁcient ATP that
promotes tumour progression25,26, and incorporate nucleotides,
amino acid and lipids required for generating a new daughter
cell. NADþ is a crucial cofactor for the redox reactions in
the metabolic pathways of cancer cells with elevated aerobic
glycolysis36. The accumulation of lactate in tumours, which
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unpaired t-test). (j) Kaplan–Meier overall survival analysis for mice treated with DPI as indicated (Kaplan–Meier analysis with the log-rank test). On: mice
were fed with doxy-containing water from 3 weeks of age. DPI: mice were treated with DPI (1.5mg kg 1 per mouse, i.p., 5 days per week) from 8 weeks of
age. Data in a,b are presented as mean±s.d. (n¼ 3). Data in c–e,g,i are representative of two independent experiments and presented as mean±s.d.
**Po0.01 for indicated comparison (one-way analysis of variance (ANOVA) with the Newman Keul’s multiple comparison test).
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generate from higher glycolytic activity, implies an increase of
NADH relative to NADþ and NADþ is insufﬁcient in cancer
cells. Also, lactate acts as strong inhibitors of PFK1 which can be
overridden by the allosteric activator, fructose-2,6-bisphosphate
(F2,6BP)27. Our recent study showed that PDAC cells rely on the
NADþ salvage pathway and reducing intracellular NADþ pools
signiﬁcantly affects glycolytic activity, cellular energy production
and tumorigenesis in PDAC cells37. Here, we found that NOX4
activation by oncogenic Kras and inactivation of p16 enables cells
to generate additional NADþ to support the glycolytic reaction
catalysed by GAPDH and thus the highly active glycolysis
required by PDAC cells. Our study showed that the NADþ
generated by NOX4 was crucial to fuel glycolysis in PDAC cells.
Suppression of NOX4 by siRNA in PDAC cells decreased NADH
oxidation and cellular NADþ levels, glycolysis and cellular
ATP production, and ultimately caused the interruption of
cancer growth. The NADþ allows glycolysis to persist and the
upregulation of NOX4 accelerates NADþ production. This role
of NOX4 in supporting active glycolysis in cancer cell metabolism
was previously unrecognized.
NOX4 is unique among the catalytic NOX subunits in
requiring the membrane subunit p22phox for ROS-producing
activity17. In cardiac ﬁbroblasts and lung and pulmonary artery
smooth muscle cells, transforming growth factor beta induces
increased expression of NOX4 (ref. 15). Insulin-like growth factor
I has been reported to activate NOX4 through transcriptional
upregulation of p22phox via an Akt-dependent pathway in
pancreatic cancer cells19. In those reports, however, the regu-
lation mechanisms of NOX4 and p22phox expression is
unexplained. The molecular mechanisms by which oncogenic
Kras and inactivated p16 upregulate the expression of NOX4 and
p22phox in PDAC cells have not been reported until now. With
the present study, we unequivocally demonstrate that NOX4
activity is induced both through transcriptional upregulation of
p22phox expression via oncogenic Kras-activated NF-kB, and
though increasing NOX4 overexpression by loss of p16-regulated
Rb-E2F pathway. Our ﬁndings not only reveal the novel function
of NOX4 in metabolic reprogramming, but also provide
a mechanistic explanation for why Kras activation and p16
inactivation are required for PDAC development.
Genetically suppression of NOX4 expression or pharmacologic
targeting NOX4 using DPI leads to metabolic disruption and
decreases pancreatic cancer growth in vitro and in vivo. It’s worth
mentioning that DPI is non-speciﬁc inhibitor for NOX4. It is a
chemical inhibitor of ﬂavoprotein-containing enzymes, including
NOX oxidases17. Our ﬁnding also revealed that the tumour
burden mice may develop resistance to DPI treatment after long
time administration. Given that inhibition of NOX4 has proven
potential for PDAC treatment and DPI just has moderate effects,
the development of potent and speciﬁc drugs that target NOX4
deserves further exploration.
In summary, our ﬁndings illuminate that NOX4, which is
regulated by oncogenic Kras and inactivation of p16 in PDAC,
may play a role in promoting glycolysis through NOX4-
dependent replenishment of NADþ levels, such that glycolysis
continues despite PFK1 and LDHA inhibition by elevated lactate.
As illustrated in Fig. 7, our ﬁndings reveal the novel function of
NOX4 in reprogramming aerobic glycolysis initiated by activated
Kras and inactivated p16 in PDAC, indicating its potential as a
therapeutic target for PDAC and other cancers.
Methods
Cell lines and cell culture. The human pancreatic cancer cell lines (AsPc-1,
BxPc-3, Colo357, Capan-1, Capan-2, Panc-1, Panc-28) were purchased from the
American Type Culture Collection (Manassas, VA, USA) and cultured under
conditions speciﬁed by the supplier. PATC-43, PATC-50, PATC-53 and PATC-66,
which were established from patient-derived xenografts (PDX), were provided by
Dr Jason B. Fleming (MD Anderson Cancer Center, USA). The mouse PDAC cell
line expressing inducible KrasG12V (mPDAC/iKras) was obtained from the
laboratories of Drs Ying and DePinho7. The immortalized/nontumorigenic
HPDE and HPNE cells were described elsewhere4,38. Other cell lines including
Panc-28/IkBaM, AsPc-1/IkBaM (both, IkBa mutant), AsPc-1/iTak1sh, HPNE/
Kras, HPNE/KrasG12V/shp16, HPDE/Kras and HPDE/KrasG12V/shp16 were
established in Dr Chiao’s laboratory and were cultured as described previously4,5,39.
All cells were negatively tested for mycoplasma contamination either by the vendor
or in house. All cell lines were authenticated by short tandem repeat (STR)
ﬁngerprinting before use at the Characterized Cell Line Core of MD Anderson
Cancer Center.
RNA isolation and qPCR with reverse transcription. Total RNA was isoltated
with TRIzol regent (# 15596-08, Life Technologies, Carlsbad, USA) and then
reverse transcribed with an iScript cDNA Synthesis Kit (Bio-Rad). The resulting
complementary DNA was analysed by qPCR performed with SYBR reagent using
the IQ5 PCR system (Bio-Rad), and data were normalized to b-Actin. Speciﬁc
primers were synthesized by Sigma-Aldrich (Louis, MO, USA) and the sequences
were described in Supplementary Table 2. The qPCR primers used for CHIP assay
were described as follows: p22phox promoter NF-kB/p65 Site 1: 50-tccgccgtttt
tctgtttcg-30 , 50-ggaaagcacagaatgcaggg-30 ; NF-kB/p65 Site 2: 50-ccttcacaccttgtcctgc
t-30 , 50-gcatctgtagggtgcaggg-30 ; NOX4 promoter E2F1 Site 1: 50-agtgctaacacgcac
atgga-30, 50-atagatgggggcaggaggtt-30 ; E2F1 Site 2: 50-gcgagggtccccacttttag-30 ,
50-cctttgtctaggggcgagc-30 .
Immunoblotting analysis. Immunoblotting analyses were performed with
precast gradient gels (Bio-Rad) using standard methods. Brieﬂy, cells were lysed in
radioimmunoprecipitation assay (RIPA) buffer and normalized using a BCA
protein assay kit (Thermo Scientiﬁc). Proteins were separated by sodiumdodecyl
sulphate-polyacrylamide gel electrophoresis (SDS–PAGE) and blotted onto a
PVDF membrane (Millipore). Membranes were probed with the speciﬁc
primary antibodies and then with peroxidase-conjugated secondary antibodies.
The bands were visualized by enhanced chemiluminescence using Hyperﬁlm ECL.
Uncropped images of immunoblots presented in the main paper are provided in
Supplementary Fig. 7. The following antibodies were used: antibodies against
NOX4 (1:2,000, ab133303), p16 (1:2,500, ab51243), p22phox (1:1,000, ab80896)
(Abcam, Cambridge, USA); Tak1 (1:1,000, #5206), Phospho(p)-Tak1 (1:1,000,
#4508), NF-kB/p65 (1:1,000, #8242), Phospho(p)-NF-kB/p65 (1:1,000, #3039),
Lamin A/C (1:1,000, #4777), p-Rb (Ser780, 1:1,000, #9307), p-Rb (Ser795, 1:2,000,
#9301), p-Rb (Ser807/811, 1:1,000, #8516), Rb (1:1,000, #9309) and E2F1 (1:1,000,
#3742) (Cell Signaling Technology, Beverly, MA, USA); Kras (1:500,sc-521), IkB-a
(1:200, #SC-371), (Santa Cruz Biotechnology, Santa Cruz, USA) and b-actin
(1:20,000, #5316) (Sigma-Aldrich, St Louis, MO).
Determination of NOX activity and NAD(P)H/NAD(P)þ levels. NOX activity
was measured by a lucigenin-derived chemiluminescence assay23. Brieﬂy, 5 mg of
homogenized protein was incubated with its substrate 100 mM NADPH or NADH
in a phosphate buffer (50mM, pH 7) containing 150mM NaCl and 1mM EGTA
for 15min, followed by addition of 5 mM lucigenin and incubation for 15min in the
dark. The chemiluminescent signal was measured by a Turner 20/20 luminometer
(Turner Designs). The intracellular levels of NADH/NADþ and NADPH/
NADPþ was measured with a NADH/NADþ -Glo Assay and NADPH/NADPþ -
Glo Assay kits (Promega Corporation, Madison, WI, USA), respectively, according
to the manufacturer’s instructions.
Determination of intracellular ROS and GSH/GSSG levels. Flow cytometry
determination of cellular O2 was performed with a BD Biosciences FACSCanto
ﬂow cytometer (BD Biosciences, San Jose, CA, USA), and the data were analysed
by the Flow-Jo software. Brieﬂy, cells were seeded in 6-well plates overnight, then
incubated with 200 ngml 1 HEt at 37 C for 60min, protected from light. After
incubation, cells were harvested with trypsin, washed twice with PBS and evaluated
by ﬂow cytometry. The intracellular levels of GSH/GSSG was measured with
a GSH/GSSG-Glo Assay kit (Promega, WI, USA) according to the manufacturer’s
instructions.
ChIP assay. Cells were grown to 80% conﬂuence, and crosslinking was performed
with 1% formaldehyde for 10min. ChIP assays were performed using a Chromatin
Immunoprecipitation Assay Kit (Millipore, Bedford, MA, USA) according to the
manufacturer’s instructions. After immunoprecipitation with an antibody against
NF-kB/p65 or E2F1 (Cell Signaling) or normal rabbit IgG, protein/DNA crosslinks
were reversed. DNA was then puriﬁed to remove the chromatin proteins and
analysed by qPCR to amplify the corresponding region in p22phox promoter
containing the two NF-kB binding sites and NOX4 promoter containing the two
E2F binding sites.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14437 ARTICLE
NATURE COMMUNICATIONS | 8:14437 |DOI: 10.1038/ncomms14437 | www.nature.com/naturecommunications 11
Metabolic measurements. For measuring oxygen consumption (OCR), cells were
trypsinized and resuspended in 1ml fresh culture medium pre-equilibrated with
21% oxygen at 37 C; the cells were then transferred to the sealed respiration
chamber of a Clark-type oxygen measuring system (Oxytherm, Hansatech
Instruments) Cellular glucose uptake was determined by using the Amplex Red
Glucose Assay Kit (Invitrogen) according to the manufacturer’s instructions.
Brieﬂy, cells in exponential growth phase were washed and incubated in fresh
medium. Medium was collected and diluted 1:400 in water. Glucose uptake was
determined by the difference in glucose concentration of each sample compared
with that of the control medium without cells. To measure lactate production, cells
with 80% conﬂuency were replenished with fresh medium. Aliquots of the medium
were removed after 12 h for measurement of lactate with an Accutrend lactate
analyzer (Roche). Cells were also counted for normalization of glucose uptake
and lactate generation. Cellular ATP contents were measured by using the
CellTiter-Glo Luminescent Cell Viability Assay kit (Promega) according to the
manufacturer’s recommendations.
Isotope labelling and metabolite analysis. Cells were seeded in 6-well plates
overnight, and replaced with medium containing U-13C6 glucose. After 1 and 3 h,
cells were washed with cold PBS once and quenched with 400ml of cold methanol.
Same volume of water containing 1 mg of norvaline was added, and cells were
scraped into 2ml tubes. Then, the chloroform (800 ml) was added. Solution was
vortex at 4 C for 30min, and centrifuged at 7,300 r.p.m. for 10min at 4 C.
The aqueous layer was collected for metabolite analysis40,41. Briﬂy, aqueous
samples were dried through speedvac and dissolved in 30 ml of 2% methoxyamine
hydrochloride in pyridine (Pierce), and sonicated for 10mins. Afterwards, samples
were kept in 37 C for 2 h and kept for another 1 h at 55 C after addition of 45ml of
MBTSTFAþ 1% TBDMCS (Pierce). Samples were transferred into GCMS running
vials (Thermo Fish Scientiﬁc). GC/MS analysis was performed using an Agilent
6890 GC equipped with a 30-m Rtx-5 capillary column for metabolites samples,
connected to an Agilent 5975B MS. The abundance of pyruvate and lactate was
calculated from the integrated signal of all potentially labelled ions for each
metabolite fragment.
RNA-mediated interference. Cells were seeded in 6-well plates at 1 105 cells per
well, respectively, and transfected using DharmaFECT transfection reagent
(Dharmacon, Lafayette, USA) with 20 nM siRNA targeted against indicated genes
or a scrambled RNA negative control. Cells were transfected for the speciﬁed time
periods depending on the subsequent analyses. ON-TARGET siRNA targeting
against the following genes were purchased from Dharmacon, including NOX4
(Target sequence: #1 50-acuaugauaucuucuggua-30 ; #2 50-gaaauuaucccaagcugua-30);
p22 phox (Target sequence: #1 50-gaagaagggcuccaccaug-30 ; #2 50-guacaugac
cgccguggug-30); p16 (Target sequence: #1 50-gaucaucagucaccgaagg-30 ; #2 50-aaacac
cgcuucugccuuu-30); NF-kB/p65 (Target sequence: #1 50-gcccuaucccuuuacguca-30 ;
#2 50-gagcaccaucaacuaugaugaguuu-30); E2F1 (Target sequence: 50-ucggagaacuu
ucagaucu-30); E2F3 (Target sequence: 50-cuucauguguaguugauua-30); E2F4 (Target
sequence: 50-cgggagaccacgauuauau-30); E2F5 (Target sequence: 50-ggugcuggcugua
auacua-30). Rescue experiments were performed by co-expressing human
NOX4 siRNA and siRNA resistant NOX4 (NOX4-R), which was synthesized by
GeneCopoeia (Rockville, USA) in AsPc-1 and Panc-28 cells.
Lentiviral transduction. The human NOX4 gene was PCR-ampliﬁed from cDNA
and DNA sequences encoding shRNAs targeting NOX4 were chosen to clone
into the pLV lentiviral vector (Biosettia). Retroviral production and infection were
performed according to the manufacturer’s instructions (Biosettia)5,37. Brieﬂy,
lentiviruses were generated by transfecting lentiviral vectors together with
packaging vector psPAX2 and envelope plasmid pMD2.G into 293T cells. After
48–72 h transfection of lentiviral vectors, viral culture supernatants from the 293T
cells were collected and the cells were infected by lentiviruses containing the
shRNA. Stable cell lines expressing NOX4 or NOX4 shRNAs were selected for 10
days with puromycin or sorted by red ﬂuorescent protein 4 days after infection,
respectively. The expression levels of NOX4 in transfected cells were determined
by qPCR and immunoblotting. Oligo sequences for NOX4 shRNA were (#1)
50-gctgtatattgatggtcct-30 and (#2) 50-gctgaagtatcaaactaat-30 .
In vivo tumorigenesis study. The experiments with mouse xenografts were
carried out according to protocols approved by the Institutional Animal Care and
Use Committee (IACUC) of MD Anderson Cancer Center. Male C57BL/6 mice
aged 5 to 6 weeks were purchased from Charles River Laboratories International.
When cell conﬂuence reached 80%, cells were harvested and washed twice with
PBS buffer. Cells were suspended in PBS buffer (1 106 cells per 50ml) with
10% Matrigel. For orthotopic implantation, each mouse was injected with 1 106
cells. The mice were killed and the tumour growth was analysed 8 weeks after
injection. Moribund animals were killed as mandated by the IACUC protocol, and
the tumour images and weights were recorded. To show the kinetics of tumour
progression, xenograft tumours were generated by subcutaneous injection of cells
into the ﬂanks of nude mouse at 2 106 cells per injection site. Tumour volumes
were measured and calculated as described previously42. Data of 5–10 animals per
experimental group are indicated in ﬁgure legends. Randomization was conducted
by using an internal computer software (Indigo). The transgenetic iKras; p53L/þ
mice generated from crossing iKras and conditional p53 knockout (p53L) alleles7,
and maintained in pathogen-free conditions at MDACC Institute. For
Doxtreatment, mice were fed with Dox water (doxy 2 g l 1, sucrose 20 g l 1).
Tissue microarray and IHC analysis. The pancreatic cancer tissue microarray was
constructed and parafﬁn sections were obtained from parafﬁn blocks of primary
PDAC and paired adjacent normal tissues of 131 pancreatic cancer patients. Tissue
specimens were collected within 1 h after surgery under a protocol approved by the
Institutional Review Board at MD Anderson Cancer Center, and written informed
consent was obtained from all patients at the time of enrolment. Tissue sections
were subjected to standard IHC analysis and photographed by a digital camera
attached to the microscope. The sections were then incubated with a rabbit
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Figure 7 | Mutant Kras and inactivated p16 orchestrate metabolic reprogramming in PDAC. The proposed working model of the function and
mechanisms of NOX4 in reprogramming aerobic glycolysis initiated by activated Kras and inactivated p16 in PDAC.
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polyclonal antibody against NOX4 (Abcam, 1:750 dilution). The staining results
were evaluated by a gastrointestinal pathologist (H. Wang).
Histopathological analysis. Mouse pancreas tumours were ﬁxed in 10% formalin,
and embedded in parafﬁn. Sections were stained with hematoxylin and eosin (HE)
according to standard procedures as previously described5. For IHC analysis of
Ki67 and NOX4, standard procedures were carried out according to the manual
(#PK-6101 and #PK-6102, Vector Laboratories). Brieﬂy, the sections were
de-waxed and rehydrated. After being retrieved antigen via unmasking solution
(#H3300, Vector Laboratories) in a steamer, slides were blocked with biotin
blocking solution (Avidin/Biotin blocking kit, SP2001, Vector Laboratories) and
1% BSA 30min, respectively; and then incubated with an anti-Ki67 (#RM-9106-S0,
Thermo Scientiﬁc) and NOX4 (ab133303, Abcam) antibodies at 4 C overnight.
Next day, all these slides were processed by ABC method (Vector Laboratories)
as described in the manufacturer’s instruction. Slides were subsequently incubated
with biotinylated secondary antibody and ABC reagent at room temperature for
30min, respectively. 3,30-diaminobenzidine (DAB, Vector Laboratories) was then
incubated as the ﬁnal chromogen, the staining time were 2 to 5min to see brown
colour under the microscope. Finally slides were counterstained with hematoxylin,
and then serially dehydrated, and sealed with permount medium after air drying.
All samples were processed under the same conditions.
Statistical analysis. For error bars in all experiments, s.d. was calculated from
three independent experiments and values represent mean±s.d. The variance
between the groups that are being statistically compared is similar. For comparison
of the statistical differences among more than two groups, one-way ANOVA and
the Newman Keul’s multiple comparison test was used. All other differences were
evaluated by the Student unpaired t-test. Survival curves were generated using the
Kaplan–Meier method and assessed using the log-rank test. Sample size was chosen
based on the need to have sufﬁcient statistical power. Differences reached statistical
signiﬁcance with Po0.05 (*) and Po0.01 (**). Statistical computations were
performed using Prism software (Graph Pad, La Jolla, CA, USA).
Data availability. The gene expression data referenced in Fig. 2g are available in
multiple cancer microarray data sets from Oncomine (https://www.oncomine.-
com//). ‘NOX4’ or ‘p22phox’ was used as keyword in the Oncomine query, ‘Cancer
versus Normal Analysis’ was used as the primary ﬁlter and ‘Pancreatic Cancer’ was
choosed as the cancer type. The cDNA microarray related to Fig. 1b were depo-
sited to Gene Expression Omnibus (GEO), the record number is GSE89422; Link:
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89422. All the other data
supporting the ﬁndings of this study are available within the article and its
Supplementary Information Files or from the corresponding authors upon
reasonable request.
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